Abstract
Patients with end-stage renal disease (ESRD) due to atypical HUS (aHUS) now have several potential options that can enable successful kidney transplantation. This editorial addresses these options by considering key factors that are important when making an individual treatment decision.
Similar content being viewed by others
References
Tran H, Chaudhuri A, Concepcion W, Grimm P (2013) Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol. doi:10.1007/s00467-013-2630-5
Saland JM, Ruggenenti P, Remuzzi G (2009) Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 20:940–949
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181
Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687
Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF (2013) Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome. Neth J Med 71:342–347
Zuber J, Le Quintrec M, Morris H, Fremeaux-Bacchi V, Loirat C, Legendre C (2013) Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 27:117–125
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:2405–2413
Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y (2004) Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 19:454–458
Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B (2002) Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 359:1671–1672
Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M (2005) Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 5:1146–1150
Loirat C, Saland J, Bitzan M (2012) Management of hemolytic uremic syndrome. Presse Med 41:e115–e135
Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH (2006) Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 6:1948–1952
Kavanagh D, Richards A, Goodship T, Jalanko H (2010) Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 36:653–659
Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomaki A, Armstrong E, Koivusalo A, Tukiainen E, Makisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS (2008) Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 8:216–221
Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ (2010) Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant 10:2142–2147
Neidich AB, Neidich EM, Lee A, Nicoletta J, Rohrer RJ, Milner LS, Cooper JT (2013) Novel use of immunoglobulin G in complement factor H missense mutation: a case report. Prog Transplant 23:213–216
Forbes TA, Bradbury MG, Goodship TH, McKiernan PJ, Milford DV (2013) Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant 17:E93–E99
Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G (2009) Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:201–206
Sanchez-Corral P, Melgosa M (2010) Advances in understanding the aetiology of atypical haemolytic uraemic syndrome. Br J Haematol 150:529–542
Alonso A, Melgosa M, lopez-Trascasa M, Navarro G, De la vega A, Sanchez-Corral P (2011) El trasplante hepático y renal combinado (THRC) normaliza el complemento y evita la recidiva del síndrome hemolítico urémico (SHU) atípico por mutación en el factor B [Abstract]. An Pediatr (Barc) 75:e1–e14
Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T (2011) Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 58:109–112
Acknowledgements
The author thanks those individual physicians who originally provided or updated verbal communications about cases. The opinions in this editorial should not be inferred to reflect the opinions of those individuals. The author has no affiliation with pedneph@lists.uchicago.edu, but thanks its administrators and participants for its open “community” use. Verbal communications unique to this report include those noted above (H. Cho, South Korea; A. Portale, USA; R. Grenda and M. Zaniew, Poland) and update confirmations from: R. Cohn, USA; E. Girardin, Switzerland; L. Milner, USA; and S. Rodriguez de Cordoba, Spain.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saland, J. Liver–kidney transplantation to cure atypical HUS: still an option post-eculizumab?. Pediatr Nephrol 29, 329–332 (2014). https://doi.org/10.1007/s00467-013-2722-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-013-2722-2